Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): the company did not repurchase shares in June.

On June 2024, Eyebright Medical Technology (Beijing) Co., Ltd. (stock code: 688050.SH) did not repurchase any shares. As of June 30, 2024, the company repurchased a total of 142,800 shares of its own stock through the Shanghai Stock Exchange trading system by centralized bidding trading, accounting for 0.075% of the current total share capital of 189,544,528 shares. The highest and lowest repurchase prices were 147.90 yuan/share and 134.10 yuan/share respectively, with a total amount paid of RMB 20,043,605.54 (excluding stamp duty, transaction commission, and other transaction fees).

Gelonghui FinanceJul 1 08:27 ET

Director, some directors, and senior management of Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH) cumulatively increased their shareholding by RMB 1.956 million.

On July 1st, Gelunhui reported that as of June 28, 2024, the chairman, some directors, and senior management of eyebright medical technology (beijing) co., ltd. (688050.SH) had accumulated 26,591 shares through the Shanghai Stock Exchange trading system in a centralized bidding trading manner, accounting for 0.014% of the current total share capital of the company. The total amount of shareholding was RMB 1.9564 million (excluding stamp duty, transaction commission, and other transaction costs), which has reached and exceeded 50% of the lower limit of the planned shareholding range. The shareholding plan has not yet been fully implemented, and the shareholding parties will continue to implement the plan.

Gelonghui FinanceJul 1 08:26 ET

Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SH): Cumulatively repurchased 142,800 company shares.

On June 4th, Gelon Healthcare (688050.SH) announced that as of May 31st, 2024, the company has repurchased a total of 142,800 shares of the company through the Shanghai Stock Exchange trading system by centralized bidding trading, accounting for 0.14% of the total share capital of the company, with the highest repurchase price of 147.90 yuan/share, the lowest price of 134.10 yuan/share, and a total payment of RMB 20,043,605.54 (excluding stamp duty, transaction commission and other transaction fees).

Gelonghui FinanceJun 4 05:28 ET

The share registration date for Aibo Healthcare (688050.SH)'s 2023 10-8 share distribution of 4.9 yuan is June 4

Aibo Healthcare (688050.SH) issued an announcement. The company will implement the 2023 annual equity distribution to all shares...

Zhitong FinanceMay 29 05:10 ET

Aibo Healthcare (688050.SH): Hyaluronic acid products fall under the category of synthetic biology

Gelonghui, May 13丨Aibo Healthcare (688050.SH) said on the investor interactive platform that hyaluronic acid products fall under the category of synthetic biology, and all other products are natural biomaterials.

Gelonghui FinanceMay 13 05:35 ET

Aibo Healthcare (688050.SH): The company did not repurchase shares in April

Gelonghui, May 7 | Aibo Healthcare (688050.SH) announced that in April 2024, the company did not repurchase shares. As of April 30, 2024, the company has repurchased 142,800 shares of the company's shares through centralized bidding transactions, accounting for 0.14% of the company's total share capital of 105,250,992 shares. The highest repurchase price was 147.90 yuan/share, the lowest price was 134.10 yuan/share, and the total capital paid was RMB 20,043,605.54 (excluding transaction fees such as stamp duty and transaction commissions).

Gelonghui FinanceMay 7 08:51 ET